chapter  19
28 Pages

Lenalidomide Therapy in MDS

ByRami Komrokji, Aristoteles Giagounidis, Alan F. List

The last decade, generally, witnessed major advancements in understanding the pathobiology of myelodysplastic syndromes (MDS) and the 5q− syndrome in particular (see chaps. 3 and 12) (1-6). For the first time, three medications for various forms of MDS were developed and approved by the Food and Drug Administration (FDA): 5-azacytidine (azacitidine), 5-aza-2′-deoxycytidine (decitabine), and lenalidomide.